Ralf A Linker

Summary

Affiliation: University of Erlangen-Nuremberg
Country: Germany

Publications

  1. ncbi Mechanisms of Oxidative Damage in Multiple Sclerosis and Neurodegenerative Diseases: Therapeutic Modulation via Fumaric Acid Esters
    De Hyung Lee
    Department of Neurology, University of Erlangen Schwabachanlage 6, Erlangen 91054, Germany e mail
    Int J Mol Sci 13:11783-803. 2012
  2. ncbi Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients
    Sven Jarius
    Neurocure, Charite University Medicine Berlin, Berlin, Germany
    J Neuroinflammation 9:14. 2012
  3. ncbi Vascular pathology in multiple sclerosis: mind boosting or myth busting?
    Anne Waschbisch
    Department of Neurology, Schwabachanlage 6, 91054 Erlangen, Germany
    Exp Transl Stroke Med 3:7. 2011
  4. ncbi Endogenous ciliary neurotrophic factor modulates anxiety and depressive-like behavior
    Isabella Peruga
    Department of Neurology, St Josef Hospital, Ruhr University Bochum, Universitatsstr 150, Bochum, Germany
    Behav Brain Res 229:325-32. 2012
  5. ncbi Modulation of autoimmune demyelination by laquinimod via induction of brain-derived neurotrophic factor
    Jan Thone
    Department of Neurology at St Josef Hospital, Group for Molecular Cell Biology, Ruhr University Bochum, Bochum, Germany
    Am J Pathol 180:267-74. 2012
  6. ncbi Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway
    Ralf A Linker
    Department of Neurology, St Josef Hospital, Ruhr University Bochum, D 44791 Bochum, Germany
    Brain 134:678-92. 2011
  7. ncbi Functional role of brain-derived neurotrophic factor in neuroprotective autoimmunity: therapeutic implications in a model of multiple sclerosis
    Ralf A Linker
    Department of Neurology St Josef Hospital, Ruhr University Bochum, D 44791 Bochum, Germany
    Brain 133:2248-63. 2010
  8. ncbi Constitutive activity of NF-kappa B in myeloid cells drives pathogenicity of monocytes and macrophages during autoimmune neuroinflammation
    Gisa Ellrichmann
    Department of Neurology, St Josef Hospital Bochum, Ruhr University Bochum, Germany
    J Neuroinflammation 9:15. 2012
  9. ncbi Inflammation modulates anxiety in an animal model of multiple sclerosis
    Isabella Peruga
    Department of Neurology, St Josef Hospital, Ruhr University Bochum, 44791 Bochum, Germany
    Behav Brain Res 220:20-9. 2011
  10. ncbi Neuronal NF-κB ablation does not influence neuro-axonal degeneration in experimental autoimmune demyelination
    De Hyung Lee
    Department of Neurology, St Josef Hospital, Ruhr University Bochum, Gudrunstr 56, 44791 Bochum, Germany
    J Neuroimmunol 246:38-42. 2012

Collaborators

Detail Information

Publications26

  1. ncbi Mechanisms of Oxidative Damage in Multiple Sclerosis and Neurodegenerative Diseases: Therapeutic Modulation via Fumaric Acid Esters
    De Hyung Lee
    Department of Neurology, University of Erlangen Schwabachanlage 6, Erlangen 91054, Germany e mail
    Int J Mol Sci 13:11783-803. 2012
    ..In summary, oxidative stress and anti-oxidative pathways are important players in MS pathophysiology and constitute a promising target for future MS therapies like FAE...
  2. ncbi Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients
    Sven Jarius
    Neurocure, Charite University Medicine Berlin, Berlin, Germany
    J Neuroinflammation 9:14. 2012
    ..However, little is known so far about the clinical impact of AQP4-Ab seropositivity...
  3. ncbi Vascular pathology in multiple sclerosis: mind boosting or myth busting?
    Anne Waschbisch
    Department of Neurology, Schwabachanlage 6, 91054 Erlangen, Germany
    Exp Transl Stroke Med 3:7. 2011
    ..Yet, the investigation of new vascular concepts as one variable in the pathophysiology of the autoimmune attack seems very worthwhile and may add to a better understanding of this devastating disorder...
  4. ncbi Endogenous ciliary neurotrophic factor modulates anxiety and depressive-like behavior
    Isabella Peruga
    Department of Neurology, St Josef Hospital, Ruhr University Bochum, Universitatsstr 150, Bochum, Germany
    Behav Brain Res 229:325-32. 2012
    ..These data imply that endogenous CNTF plays a pivotal role for the structural maintenance of hippocampal functions and thus has an important impact on the modulation of affective behavior in rodent models of anxiety and depression...
  5. ncbi Modulation of autoimmune demyelination by laquinimod via induction of brain-derived neurotrophic factor
    Jan Thone
    Department of Neurology at St Josef Hospital, Group for Molecular Cell Biology, Ruhr University Bochum, Bochum, Germany
    Am J Pathol 180:267-74. 2012
    ..Consistent with immunomodulatory properties, laquinimod skewed monocytes toward a regulatory phenotype and also acted via modulation of BDNF, which may contribute to neuroprotection in MS patients...
  6. ncbi Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway
    Ralf A Linker
    Department of Neurology, St Josef Hospital, Ruhr University Bochum, D 44791 Bochum, Germany
    Brain 134:678-92. 2011
    ....
  7. ncbi Functional role of brain-derived neurotrophic factor in neuroprotective autoimmunity: therapeutic implications in a model of multiple sclerosis
    Ralf A Linker
    Department of Neurology St Josef Hospital, Ruhr University Bochum, D 44791 Bochum, Germany
    Brain 133:2248-63. 2010
    ..Our data imply a functional role of brain-derived neurotrophic factor in autoimmune demyelination by mediating axon protection...
  8. ncbi Constitutive activity of NF-kappa B in myeloid cells drives pathogenicity of monocytes and macrophages during autoimmune neuroinflammation
    Gisa Ellrichmann
    Department of Neurology, St Josef Hospital Bochum, Ruhr University Bochum, Germany
    J Neuroinflammation 9:15. 2012
    ..In summary, myeloid cell derived NF-κB plays a crucial role in autoimmune inflammation of the CNS and drives a pathogenic role of monocytes and macrophages independently from T-cells...
  9. ncbi Inflammation modulates anxiety in an animal model of multiple sclerosis
    Isabella Peruga
    Department of Neurology, St Josef Hospital, Ruhr University Bochum, 44791 Bochum, Germany
    Behav Brain Res 220:20-9. 2011
    ..These data imply that chronic inflammation in the CNS may impact on emotional responses in rodent models of anxiety...
  10. ncbi Neuronal NF-κB ablation does not influence neuro-axonal degeneration in experimental autoimmune demyelination
    De Hyung Lee
    Department of Neurology, St Josef Hospital, Ruhr University Bochum, Gudrunstr 56, 44791 Bochum, Germany
    J Neuroimmunol 246:38-42. 2012
    ..In conclusion, neuronal NF-κB ablation does not modulate neurodegeneration in autoimmune demyelination...
  11. ncbi Central nervous system rather than immune cell-derived BDNF mediates axonal protective effects early in autoimmune demyelination
    De Hyung Lee
    Department of Neurology, Friedrich Alexander University Erlangen, Germany
    Acta Neuropathol 123:247-58. 2012
    ..In summary, our data argue for an early window of therapeutic opportunity where modulation of BDNF may exert neuroprotective effects in experimental autoimmune demyelination...
  12. ncbi Stability of cognitive functions under mitoxantrone therapy in patients with progressive multiple sclerosis: a pilot analysis
    Alexandra Schröder
    Department of Neurology, St Josef Hospital, Ruhr University Bochum, Gudrunstr 56, 44791 Bochum, Germany
    Clin Neurol Neurosurg 113:527-30. 2011
    ..Mitoxantrone (MX) is a potent immunosuppressant that is licensed as escalation therapy for the treatment of active multiple sclerosis (MS)...
  13. ncbi Efficacy of fumaric acid esters in the R6/2 and YAC128 models of Huntington's disease
    Gisa Ellrichmann
    Department of Neurology, St Josef Hospital, Ruhr University Bochum, Bochum, Germany
    PLoS ONE 6:e16172. 2011
    ..In conclusion, DMF may exert beneficial effects in mouse models of HD. Given its excellent side effect profile, further studies with DMF as new therapeutic approach in HD and other neurodegenerative diseases are warranted...
  14. ncbi Fumarates for the treatment of multiple sclerosis: potential mechanisms of action and clinical studies
    Ralf A Linker
    Department of Neurology, St Josef Hospital Ruhr University Bochum, Bochum, Germany
    Expert Rev Neurother 8:1683-90. 2008
    ..Presently, two Phase III studies are ongoing to investigate the clinical long-term efficacy of BG-12. In summary, FAE are potential candidates that may open a new therapeutic option for relapsing-remitting MS in the near future...
  15. ncbi Spotlight on fumarates
    De Hyung Lee
    Department of Neurology at St Josef Hospital, Ruhr University Bochum, Bochum, Germany
    Int MS J 15:12-8. 2008
    ..Currently, two multicentre, Phase III studies for testing clinical efficacy in RRMS are initiated. In view of their profile, FAE compounds may have the potential to add to our therapeutic options in RRMS in the future...
  16. ncbi Proteome profiling in murine models of multiple sclerosis: identification of stage specific markers and culprits for tissue damage
    Ralf A Linker
    Department of Neurology, St Josef Hospital, Ruhr University, Bochum, Germany
    PLoS ONE 4:e7624. 2009
    ..In summary, our findings underscore the value of proteome analyses as screening method for stage specific biomarkers and for the identification of new culprits for tissue damage in chronic autoimmune demyelination...
  17. ncbi Identification and development of new therapeutics for multiple sclerosis
    Ralf A Linker
    Department of Neurology, St Josef Hospital, Ruhr University Bochum, Gudrunstrasse 56, 44791 Bochum, Germany
    Trends Pharmacol Sci 29:558-65. 2008
    ....
  18. ncbi Successful management of natalizumab-associated progressive multifocal leukoencephalopathy and immune reconstitution syndrome in a patient with multiple sclerosis
    Alexandra Schröder
    Department of Neurology, St Josef Hospital, Ruhr University Bochum, Gudrunstrasse 56, 44791 Bochum, Germany
    Arch Neurol 67:1391-4. 2010
    ..To describe a case of successful clinical management of natalizumab-associated progressive multifocal leukoencephalopathy (PML) and immune reconstitution syndrome (IRIS) in a patient with multiple sclerosis...
  19. ncbi Glatiramer acetate treatment normalizes deregulated microRNA expression in relapsing remitting multiple sclerosis
    Anne Waschbisch
    Department of Neurology, Friedrich Alexander University, Erlangen Nurnberg, Germany
    PLoS ONE 6:e24604. 2011
    ....
  20. ncbi Successful treatment of cerebellar ataxia and tremor in multiple sclerosis with topiramate: a case report
    Alexandra Schroeder
    Department of Neurology, St Josef Hospital, Ruhr University Bochum, Bochum, Germany
    Clin Neuropharmacol 33:317-8. 2010
    ..Multiple sclerosis immunotherapy was not changed in this period. In conclusion, topiramate may be a new therapeutic option to treat cerebellar tremor and ataxia in patients with multiple sclerosis...
  21. ncbi Plasmapheresis for neurological disorders
    Alexandra Schröder
    Department of Neurology, St Josef Hospital, Ruhr University Bochum, Gudrunstrasse 56, 44791 Bochum, Germany
    Expert Rev Neurother 9:1331-9. 2009
    ..Adding to its increasing application in clinical practice, the procedure is usually well tolerated. Possible adverse reactions mainly relate to vascular access, the use of replacement fluids and the need for anticoagulation...
  22. ncbi Use of intravenous immunoglobulin and plasma exchange in neurological disease
    Ralf A Linker
    Department of Neurology, St Josef Hospital, Ruhr University, Bochum, Germany
    Curr Opin Neurol 21:358-65. 2008
    ....
  23. ncbi Failure of natalizumab to prevent relapses in neuromyelitis optica
    Ingo Kleiter
    Department of Neurology, University Medical Center Regensburg, Regensburg, Germany
    Arch Neurol 69:239-45. 2012
    ..To describe first experiences with the integrin inhibitor natalizumab, given to patients with suspected relapsing-remitting multiple sclerosis (MS) who were later diagnosed with aquaporin 4-positive neuromyelitis optica (NMO)...
  24. ncbi IL-6 transsignalling modulates the early effector phase of EAE and targets the blood-brain barrier
    Ralf A Linker
    Department of Neurology, St Josef Hospital Bochum, Ruhr University Bochum, Bochum, Germany
    J Neuroimmunol 205:64-72. 2008
    ..We conclude that IL-6 transsignalling may play a role in autoimmune inflammation of the CNS mainly by regulating early expression of adhesion molecules, possibly via cellular networks at the blood-brain barrier...
  25. ncbi Polymorphisms in genes encoding leptin, ghrelin and their receptors in German multiple sclerosis patients
    Linda K Rey
    Department of Human Genetics, Ruhr University Bochum, Universitatsstrasse 150, 44801 Bochum, Germany
    Mol Cell Probes 25:255-9. 2011
    ..However, a modest effect of GHSR variation cannot be ruled out and needs to be further evaluated in future studies...
  26. ncbi Subcutaneous immunoglobulin infusion: a new therapeutic option in chronic inflammatory demyelinating polyneuropathy
    De Hyung Lee
    Department of Neurology at St Josef Hospital, Ruhr University Bochum, Gudrunstrasse 56, D 44791 Bochum, Germany
    Muscle Nerve 37:406-9. 2008
    ..SCIg may represent an effective new therapeutic option in CIDP and is associated with a cost reduction of at least 50% compared to IVIg therapy...